Loading tool details…
Compare listed plans and check current offer terms with Owkin
per month
per month
per month
This guide does not establish that Owkin has an active coupon, education discount, or seasonal promotion. Confirm current offers on the vendor's website before paying.
Federated learning is a machine learning approach where algorithms are sent to data sources, such as hospitals, rather than centralizing data in one location. Owkin describes MOSAIC as a platform that can train models across participating medical centers while keeping raw patient data within institutional environments and aggregating model learnings instead.
MSIntuit CRC is Owkin's FDA 510(k)-cleared AI diagnostic tool for detecting microsatellite instability in colorectal cancer from standard H&E-stained pathology slides. MSI status can affect treatment decisions, including immunotherapy eligibility. Procurement teams should review FDA clearance documentation and Owkin validation materials for exact intended use, performance, and workflow details.
Owkin differentiates through its federated learning approach, which is designed to support access to real-world hospital data without centralization. Recursion Pharmaceuticals focuses on high-throughput biological experimentation and proprietary cellular imaging datasets. Insilico Medicine emphasizes generative AI for de novo molecule design and has its own clinical-stage drug candidates. Owkin's relative strength is hospital-connected biomedical AI, digital pathology, and oncology-focused clinical data collaboration.
Owkin primarily partners with large pharmaceutical companies, academic medical centers, and hospital networks. The platform is not presented as a self-service product for individual researchers or clinical practitioners. Engagements appear to require negotiated enterprise or research collaboration agreements, with commercial terms varying by scope.
Owkin's AI research and diagnostic pipeline spans multiple oncology indications including colorectal cancer, non-small cell lung cancer, breast cancer, mesothelioma, and hepatocellular carcinoma. Its computational pathology and biomarker discovery capabilities are positioned for solid tumor settings where digitized pathology slides and clinical outcome data are available through appropriate partnerships.
Check the vendor’s current pricing, eligibility, and billing terms
Get Started with Owkin →Listed prices may change. Confirm current prices and offer terms with the vendor.